What question did this study set out to answer?

To pool genomic data and assess the clinical relevance of somatic mutations in chronic phase CML at diagnosis.

December 8, 2025BloodOpen Access

Somatic mutations at diagnosis in patients with chronic Phase CML receiving frontline imatinib are associated with a higher rate of treatment failure: First analysis from the international CML foundation (iCMLf) genomics alliance on the harmony platform

View Full Paper

Ask AI

Bookmark

Authors

Analysis reveals somatic mutations influence risk stratification and clinical outcomes in chronic phase CML patients treated with imatinib.

To pool genomic data and assess the clinical relevance of somatic mutations in chronic phase CML at diagnosis.
Utilized the HARMONY Platform to collect genomic data from multiple centers.
Analyzed whole exome and targeted gene panel sequencing data from 468 patients on imatinib.
Applied Kaplan–Meier survival curves to evaluate time-to-event outcomes.
20.5% of patients had somatic mutations at diagnosis.
Five-year progression-free survival was 76.3% for patients with mutations vs 83.1% without.
Five-year failure-free survival was significantly lower for patients with mutations (43.8% vs 65.2%).

Rinke et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Analysis reveals somatic mutations influence risk stratification and clinical outcomes in chronic phase CML patients treated with imatinib.

To pool genomic data and assess the clinical relevance of somatic mutations in chronic phase CML at diagnosis.
Utilized the HARMONY Platform to collect genomic data from multiple centers.
Analyzed whole exome and targeted gene panel sequencing data from 468 patients on imatinib.
Applied Kaplan–Meier survival curves to evaluate time-to-event outcomes.
20.5% of patients had somatic mutations at diagnosis.
Five-year progression-free survival was 76.3% for patients with mutations vs 83.1% without.
Five-year failure-free survival was significantly lower for patients with mutations (43.8% vs 65.2%).

Rinke et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark